PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
Want to see PDSB full AI Analyst Report?
PDSB Stock Chart & Stats
$1.28
-$0.09(-5.36%)
At close: 4:00 PM EST
$1.28
-$0.09(-5.36%)
Day’s Range― - ―
52-Week Range$0.51 - $1.92
Previous CloseN/A
Volume197.50K
Average Volume (3M)663.93K
Market Cap
$75.91M
Enterprise Value$5.24B
Total Cash (Recent Filing)$26.71M
Total Debt (Recent Filing)$5.19B
Price to Earnings (P/E)―
Beta2.94
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding55,815,655
10 Day Avg. Volume1,079,749
30 Day Avg. Volume663,935
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.86
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap68.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-346.11K
Enterprise Value/Ebitda-172.78
Forecast
1Y Price Target
$7.50Price Target Upside485.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyRobust clinical activity reported for PDS01ADC combined with HAIP, including an objective response rate of about seventy-eight percent and notable survival gains in colorectal liver metastases, supports the therapy's potential to improve treatment outcomes.
Regulatory PathwayFormal alignment with the FDA on using progression-free survival as an interim primary endpoint positions the program for a clearer accelerated approval pathway and a concrete interim regulatory milestone.
Trial Efficiency And Cash BurnAmending the late-stage trial to prioritize progression events reduces required sample size and trial duration, which should lower operational costs and cash burn.
Bears Say
Data RobustnessA small patient dataset and limited ability to compare across studies increase uncertainty around efficacy conclusions and underscore the need for larger confirmatory trials.
Enrollment And Timeline VisibilityUndisclosed updated enrollment targets create uncertainty about the trial's exact size and timeline, reducing visibility into when key data and milestones will be reached.
Full Approval RiskRetaining median overall survival as the primary endpoint for full approval means longer-term survival data will still be required to achieve full regulatory clearance.
PDS Biotechnology News
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $0.51 and its highest was $1.92 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
PDS Biotechnology Corporation’s market cap is $75.91M.
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is May 20, 2026 which is in 33 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Mar 30, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.07.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 55,815,655 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -0.924%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Currently, no hedge funds are holding shares in PDSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (485.94% Upside)
$7.50 (485.94% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.07%
12-Months-Change
Fundamentals
Return on Equity
-241.96%
Trailing 12-Months
Asset Growth
-32.69%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
PDSB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical and IP progress — notably strong VERSATILE-002 survival data, promising early PDS01ADC signals, and FDA alignment on a protocol amendment that may accelerate regulatory timelines. Financials showed cost reductions and an improved net loss, but were tempered by a relatively small cash balance, higher net interest expense, and limited disclosure of the revised Phase III sample size and powering details. Overall, the positives around clinical momentum, patent protection into the 2040s, and decreased operating expenses outweigh the financial and execution uncertainties noted.View all PDSB earnings summariesPDSB Stock 12 Month Forecast
Average Price Target
$7.50
▲(485.94% Upside)
Technical Analysis
Ownership Overview
1.51%
Insiders
3.84% Mutual Funds
0.37% Other Institutional Investors
91.20% Public Companies and
Individual Investors